

09/609,721

Page 2

Xaa<sub>2</sub> is an amino acid selected from the group consisting of Met, Thr, Cys and Ile and Xaa<sub>3</sub> is absent or between one and 7 amino acids.

2. (amended) The peptide ligand of claim 1 having the following formula:

Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Gly-Pro-Gly-Cys-Xaa<sub>3</sub> (SEQ ID NO:92)

wherein Xaa<sub>1</sub> is absent or between one and fourteen amino acids; and Xaa<sub>2</sub> is an amino acid selected from the group consisting of Met, Ile, Thr or Cys and Xaa<sub>3</sub> is absent or between one and seven amino acids.

3. (amended) The peptide ligand of claim 2 having the following formula:

Xaa<sub>1</sub>-Cys-Ile-Gly-Pro-Gly-Cys-Xaa<sub>3</sub> (SEQ ID NO:161)

wherein Xaa<sub>1</sub> is absent or between one and seven amino acids.

5. (amended) The peptide ligand of claim 3 having the following formula:

Xaa<sub>1</sub>-Trp-Gly-Cys-Ile-Gly-Pro-Gly-Cys-Xaa<sub>3</sub> (SEQ ID NO:93)

wherein Xaa<sub>1</sub> is absent or between one and five amino acids.

6. (amended) The peptide ligand of claim 5 having the following formula:

Xaa<sub>1</sub>-Glu-Xaa<sub>2</sub>-Trp-Gly-Cys-Ile-Gly-Pro-Gly-Cys-Xaa<sub>3</sub>-Xaa<sub>4</sub>-Leu-Xaa<sub>5</sub> (SEQ ID NO:87)

wherein Xaa<sub>1</sub> is absent or between one and three amino acids, Xaa<sub>2</sub> is an amino acid,

Xaa<sub>3</sub> is an amino acid,

Xaa<sub>4</sub> is an amino acid and

Xaa<sub>5</sub> is absent or between one and four amino acids.

09/609,721

Page 3

7. (amended) The peptide ligand of claim 6 wherein Xaa is absent or selected from the group consisting of

Gln-Arg-Asn-  
Leu-Ser-Pro-  
Glu-Asn-Trp-  
Ala-Ser-His-  
Lys-Leu-Asn-  
Thr-Gln-Ala-  
Ala-Pro-Arg-  
Gln-Val-Tyr-  
Arg-Thr-Glu-  
Phe-Ala-Gly-  
Thr-Ala-Arg-  
Arg-Pro-His-  
Asn-Val-Cys-  
Cys-Ile-Asp-  
Tyr-Glu-Trp-  
Arg-Trp-Asp-  
His-Trp-Met-  
Asn-Trp-Pro-  
Phe-Asn-Trp-  
Phe-Ser-Gly-  
Gly-Gly-Trp-  
Leu-Trp-Phe-  
Gly-Ile-Pro-  
Trp-Trp-Thr-  
Leu-Gly-Trp-  
Ser-Pro-Trp-  
Arg-Gly-Trp-,

Xaa, is selected from the group consisting of:

Ala, Thr, Met, Val, Arg, Glu, Asp, Ser, Gln, Pro, Gly, Phe and Lys,

a2  
cont

09/609,721

Page 4

Xaa<sub>1</sub> is selected from the group consisting of:

Glu, Lys, Arg, Asp, Ser, Ala, Asn, Gly, Pro and Gln,

Xaa<sub>2</sub> is selected from the group consisting of:

Met, Phe, Ala, Met, Cys, Gln, Glu, Ala, Trp, Phe, Leu, Val, Tyr, Trp, and

Xaa<sub>3</sub> is a four amino acid peptide having the following formula:

-Xaa<sub>1</sub>-Xaa<sub>2</sub>-Cys-Xaa<sub>4</sub>.

8. (amended) The peptide ligand of claim 7 wherein -Xaa<sub>1</sub>-Xaa<sub>2</sub>-Cys-Xaa<sub>3</sub> is selected from the group consisting of:

-Gln-Ala-Cys-Met (SEQ ID NO:102)

-Leu-Gln-Cys-Trp (SEQ ID NO:103)

-Met-Ser-Cys-Val (SEQ ID NO:104)

-Leu-Arg-Cys-Ile (SEQ ID NO:105)

-Gln-Ala-Cys-Leu (SEQ ID NO:106)

-Leu-Ser-Cys-Leu (SEQ ID NO:107)

-Ile-Gly-Cys-Leu (SEQ ID NO:108)

-Leu-Ala-Cys-Leu (SEQ ID NO:109)

-Leu-Ser-Cys-Ile (SEQ ID NO:110)

-Met-Asn-Cys-Leu (SEQ ID NO:111)

-Leu-Arg-Cys-Leu (SEQ ID NO:112)

-Leu-Lys-Cys-Leu (SEQ ID NO:113)

-Leu-Gly-Cys-Leu (SEQ ID NO:114)

-Leu-Asn-Cys-Ile (SEQ ID NO:115)

-Met-Gly-Cys-Leu (SEQ ID NO:116) and

-Met-Ala-Cys-Leu (SEQ ID NO:117).

9. (amended) The peptide ligand of claim 6 wherein Xaa<sub>1</sub> is a four amino acid peptide having the following formula

-Cys-Xaa<sub>6</sub>-Xaa<sub>10</sub>-Cys

wherein Xaa<sub>6</sub> is an amino acid and Xaa<sub>10</sub> is an amino acid.

09/609,721

Page 5

10. (amended) The peptide ligand of claim 9 wherein Xaa<sub>1</sub> is selected from the group consisting of:

- a<sup>2</sup>  
cont
- Cys-Ala-Trp-Cys (SEQ ID NO:118)
  - Cys-Ser-Trp-Cys (SEQ ID NO:119)
  - Cys-Glu-Pro-Cys (SEQ ID NO:120)
  - Cys-Asp-Trp-Cys (SEQ ID NO:121)
  - Cys-Glu-Trp-Cys (SEQ ID NO:122)
  - Cys-Asn-Trp-Cys (SEQ ID NO:123) and
  - Cys-Gly-Trp-Cys (SEQ ID NO:124).
- 

21. (amended) A polypeptide which comprises:

(a) a peptide ligand having the following formula:

Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Gly-Pro-Gly-Cys-Xaa<sub>3</sub>,

a<sup>3</sup>

wherein Xaa<sub>1</sub> is absent or between one and fourteen amino acids; and Xaa<sub>2</sub> is an amino acid selected from the group consisting of Met, Ile, Thr or Cys and Xaa<sub>3</sub> is absent or between one and seven amino acids and

(b) an immunoglobulin constant region sequence.

---

30. (amended) A pharmaceutical composition comprising a peptide ligand having the following formula:

a<sup>4</sup>

Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Gly-Pro-Gly-Cys-Xaa<sub>3</sub>,

wherein Xaa<sub>1</sub> is absent or between one and fourteen amino acids; and Xaa<sub>2</sub> is an amino acid selected from the group consisting of Met, Ile, Thr or Cys and Xaa<sub>3</sub> is absent or between one and seven amino acids and pharmaceutically acceptable excipient.

---

Please add the following new claims:

a<sup>5</sup>

39. (new) A composition comprising a peptide ligand having the following formula:

Xaa<sub>1</sub>-Cys-Xaa<sub>2</sub>-Gly-Pro-Gly-Cys-Xaa<sub>3</sub>,

wherein Xaa<sub>1</sub> is absent or between one and fourteen amino acids;